Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses pharmacists' educational needs on biosimilars.
Transcript:
I think it's not just pharmacists. It's the overall healthcare team and provider team. Right now I think we're still in a new and emerging area. Hopefully, shortly we’ll also see biosimilar insulin on the market, too, and that’ll be a great discussion; that’s a big topic right now in the biosimilar area.
For pharmacists, I think there needs to be a lot more discussion on how drugs are getting approved, what is the regulatory process: phase 1, phase 3. We also need to go over and delineate a lot more discussion on the global implementation of biosimilars to help provide more of a foundation for discussions here in the [United States, US].
Other areas which are requiring a lot more education: [continuing education, CE], review articles as well to get the information out there in the next few years. We need more discussion on [pharmacy and therapeutics, P and T] implementation, how that works. Reimbursement is going to be critical in this area, and there is a pure lack of understanding of reimbursement.
In fact, if there's one thing that can be done, it’s to create a level playing field for the understanding of reimbursement, both from a private payer and also government payer type of situation to make sure everyone is on the same page. I feel the more we talk about this, the more the education goes on on this, it will only help better provide resources for patients, but also institutions. So pharmacists really need to be aware of that as well.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.